Skip to main navigation

About Us
- Our Core Values
- Our Team
Our Science
Clinical Research
- Pipeline
- RESOLVE
Patients
- Eosinophilic Esophagitis
- Expanded Access Program
Careers
Investors

Events & Presentations

News & Events

News Releases
Events & Presentations

Upcoming Events

More events to come.

Corporate Presentation

Eupraxia Investor Presentation Thumbnail Image

Past Events

Morgan Stanley 24th Annual Global Healthcare Conference

Sep 15 - September 16, 2026

Location

New York, NY

H.C. Wainwright 28th Annual Global Investment Conference

September 14, 2026 | 2:00 PM EDT

Location

New York, NY

Cantor Global Healthcare Conference

September 11, 2026 | 9:45 AM EDT

Location

New York, NY

Virtual KOL Event to Discuss Upper Endoscopies and EoE Patients - Understanding How EP-104GI Administration Fits Within Clinical Practice

July 30, 2026 | 12:00 PM EDT

Location

Virtual

Presentation Slides

Jefferies Global Healthcare Conference

June 3, 2026 | 5:30 PM EDT

Location

New York, NY

Virtual Investor Event at Digestive Disease Week 2026

May 4, 2026 | 8:00 AM EDT

Location

Chicago, Illinois

Access the replay

2026 Bloom Burton & Co. Healthcare Investor Conference

April 21, 2026 | 11:00 AM EDT

Location

Toronto, ON

Raymond James Biotech Innovation Symposium

April 14, 2026

Location

New York, NY

Webinar - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

October 1, 2025 | 8:00 AM EDT

H.C. Wainwright 27th Annual Global Investment Conference

September 9, 2025 | 11:00 AM EDT

Location

New York, NY

Current page 1
Page 2
Page 3
Next page
Last page

Investor Contact

Kevin Gardner
Investor relations on behalf of Eupraxia Pharmaceuticals

draftskgardner@lifesciadvisors.com
draftsinvestors@eupraxiapharma.com

phone_iphone +617-283-2856

Subscribe to our Email Alerts

Email Address Required

Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.

Vancouver lab & office:
Eupraxia Pharmaceuticals
2198 Yukon St,
Vancouver, BC, V5Y 3P1
Canada

Seattle office:
Eupraxia Pharmaceuticals
5310 Carillon Point
Kirkland, WA 98033
USA

Get in Touch

Contact
Careers
250-590-3968

Follow us on :

Privacy Policy
Term of Use
IR Email Alerts

© 2026 Eupraxia Pharmaceuticals Inc. All rights reserved.

Search Investors

Search this site